KRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer

Key Takeaways

A previous study showed a confirmed objective response rate of 42.9% with the KRAS G12C inhibitor adagrasib in previously treated patients with NSCLC.

In this phase III trial, median progression-free survival was 5.5 months for those who received adagrasib versus 3.8 months for those who received docetaxel.

The findings confirm that adagrasib is an efficacious treatment option for this patient population after prior chemotherapy and immunotherapy.

Treatment with adagrasib (Krazati) significantly improved progression-free-survival (PFS) in previously treated patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) compared with docetaxel, the phase III KRYSTAL-12 trial showed.

In the intention-to-treat population, median PFS was 5.5 months among those who rece